Private Investor Briefing: How AI is catalyzing new precision diagnostics that deserve greater investor attention

Precision medicine tools and in vitro diagnostics segments offer significantgrowth potential (7 – 17% CAGR to 2034). With the recent evolution from genomics to multiomics and application of AI/ ML techniques to large data sets, early stage ventures have emerged, from predictive diagnostic platforms, to pharmacogenics and liquid biopsy, to capture this growth trend. The time is right for private investors to explore precision diagnostics, with partnership and exit opportunities via life sciences tools, diagnostics and biopharma corporates.

Download

Cover of a whitepaper prodiced by Gloucester Ventures. there is a gray box over it that is slightly transparent. The text "Part II: Coming Soon" sits in the center of the image.

Resource

Coming Soon: Part II

Building on Part I in our series, we believe that the adoption of genAI/ agentic AI in precision diagnostics will unlock even more potential for investors. This is based on five 'must have's':

Ready to use, available data for precision Dx
Alignment of AI advancements with regulation around Dx models and data
Harmonized, standardized Dx systems, not tests
Actionable, genAI/ agentic-based dashboards for biopharma, clinician and patient decisioning
Emergence of new, robust precision Dx business models alongside reimbursement

Building on Part I in our series, we believe that the adoption of genAI/ agentic AI in precision diagnostics will unlock even more potential for investors. This is based on five 'must have's':

Ready to use, available data for precision Dx
Alignment of AI advancements with regulation around Dx models and data
Harmonized, standardized Dx systems, not tests
Actionable, genAI/ agentic-based dashboards for biopharma, clinician and patient decisioning
Emergence of new, robust precision Dx business models alongside reimbursement